US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Cabaletta Bio, Inc. - Common Stock (NQ:CABA)

2.080 +0.080 (+4.00%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cabaletta Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cramer: This REIT Is 'A Little Too Dicey'; As For Marathon Digital, 'Own The Pure' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding onto Regions Financial Corporation (NYSE: RF). 
Via Benzinga
News headline image
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 12/8
Via Investor Brand Network
News headline image
Analyst Ratings for Cabaletta Bio ↗
 
Via Benzinga
News headline image
Where Cabaletta Bio Stands With Analysts ↗
 
Via Benzinga
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 11/9
Via Investor Brand Network
News headline image
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Cabaletta Bio
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Cabaletta Bio: Q3 Earnings Insights ↗
 
Via Benzinga
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 10/24
Via Investor Brand Network
News headline image
7 Analysts Have This to Say About Cabaletta Bio ↗
 
Via Benzinga
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 10/23
Via Investor Brand Network
News headline image
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
News headline image
Verint Reports Strong Earnings, Joins Semtech, Alphabet And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining more than 100 points on Thursday. 
Via Benzinga
Topics Stocks
News headline image
The Latest Analyst Ratings for Cabaletta Bio ↗
 
Via Benzinga
News headline image
Leslie's Posts Weak Earnings, Joins Las Vegas Sands, Verve Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
U.S. stock futures traded higher this morning, with the Dow Jones futures gaining around 100 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From Cabaletta Bio
Via GlobeNewswire
News headline image
Crude Oil Surges 2%; Tharimmune Shares Plummet ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Tuesday. The Dow traded up 0.27% to 35,429.20 while the NASDAQ rose 0.12% to 14,258.32. The... 
Via Benzinga
Topics Stocks
News headline image
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Cantor Fitzgerald Maintains Overweight Rating for Cabaletta Bio: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
From Cellares
Via Business Wire
News headline image
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
From Cabaletta Bio
Via GlobeNewswire
News headline image
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
From Cabaletta Bio
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >